Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen.

A group of 36 patients in the hematology department of Saint-Antoine Hospital, Paris, France, was on chemotherapy. The patients were also given antiacid drugs to prevent gastrointestinal toxicity and itraconazole as prophylaxis against aspergillosis. The antifungal drug was given as 100-mg capsules three times a day shortly after meals. The plasma itraconazole and hydroxyitraconazole concentrations were measured by high-performance liquid chromatography at steady state. Of 36 patients, 29 (81%) had adequate plasma itraconazole concentrations (> or = 250 ng/ml) after 8 +/- 2 days. The 7 patients with low plasma itraconazole concentrations were given 200 mg three times a day. Of the 36 patients, 34 (94%) had effective plasma concentrations within 2 weeks of the beginning of treatment. The two remaining patients were lost to follow-up. The proposed itraconazole regimen provides effective prophylaxis against aspergillosis and represents a substantial economic advantage over a single daily dose of 400 to 600 mg. The marked intrapatient and interpatient variations in plasma itraconazole indicate the need for regular therapeutic drug monitoring to ensure effective plasma itraconazole concentrations in all neutropenic patients.

[1]  A. Peer,et al.  The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[2]  G. Cheymol,et al.  A rapid and specific liquid chromatographic assay for the determination of itraconazole and hydroxyitraconazole in plasma. , 1997, Therapeutic drug monitoring.

[3]  G. Cheymol,et al.  Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. , 1996, Therapie.

[4]  C. Berthou,et al.  Aspergilloses traitées par l'itraconazole: analyse de 64 cas , 1993 .

[5]  M. Rochet,et al.  Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. , 1992, European journal of cancer.

[6]  A. Prentice,et al.  Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. , 1991, The Journal of antimicrobial chemotherapy.

[7]  J. V. D. van der Meer,et al.  The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. , 1991, The Journal of infection.

[8]  B. Dupont.  Itraconazole therapy in aspergillosis: study in 49 patients. , 1990, Journal of the American Academy of Dermatology.

[9]  J. Cutsem.  The In‐vitro Antifungal Spectrum of Itraconazole , 1989 .

[10]  G. Verhoef,et al.  Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels , 1989, Mycoses.

[11]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.

[12]  S. Tanaka,et al.  Mitochondrial Kinetics During Mitosis in Cryptococcus neoforrnans an Ultrastructural Study , 1989, Mycoses.

[13]  J. Graybill,et al.  Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[14]  J. V. van Cutsem,et al.  Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. , 1987, Reviews of infectious diseases.

[15]  M. H. Spector,et al.  Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. , 1979, Cancer treatment reviews.